title: Imatinib induced pyoderma gangrenosum.
authors.affiliation: Department of Experimental Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK, .
authors.forename: D J
authors.initials: DJ
authors.lastname: Pinato
authors.forename: R
authors.initials: R
authors.lastname: Sharma
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000009:adverse effects*; D011241:Prednisone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects*; D012008:Recurrence; D028761:Withholding Treatment
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011241:Prednisone